Literature DB >> 12450890

Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers.

Marek Naruszewicz1, Marie-Louise Johansson, Danuta Zapolska-Downar, Hanna Bukowska.   

Abstract

BACKGROUND: The short-chain fatty acids formed in the human colon by the bacterial fermentation of fiber may have an antiinflammatory effect, may reduce insulin production, and may improve lipid metabolism. We previously showed in hypercholesterolemic patients that supplementation with the probiotic bacteria Lactobacillus plantarum 299v significantly lowers concentrations of LDL cholesterol and fibrinogen.
OBJECTIVE: We determined the influence of a functional food product containing L. plantarum 299v on lipid profiles, inflammatory markers, and monocyte function in heavy smokers.
DESIGN: Thirty-six healthy volunteers (18 women and 18 men) aged 35-45 y participated in a controlled, randomized, double-blind trial. The experimental group drank 400 mL/d of a rose-hip drink containing L. plantarum 299v (5 x 10(7) colony-forming units/mL); the control group consumed the same volume of product without bacteria. The experiment lasted 6 wk and entailed no changes in lifestyle.
RESULTS: Significant decreases in systolic blood pressure (P < 0.000), leptin (P < 0.000), and fibrinogen (P < 0.001) were recorded in the experimental group. No such changes were observed in the control group. Decreases in F(2)-isoprostanes (37%) and interleukin 6 (42%) were also noted in the experimental group in comparison with baseline. Monocytes isolated from subjects treated with L. plantarum showed significantly reduced adhesion (P < 0.001) to native and stimulated human umbilical vein endothelial cells.
CONCLUSION: L. plantarum administration leads to a reduction in cardiovascular disease risk factors and could be useful as a protective agent in the primary prevention of atherosclerosis in smokers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12450890     DOI: 10.1093/ajcn/76.6.1249

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  85 in total

1.  Lactobacillus acidophilus Increases the Anti-apoptotic Micro RNA-21 and Decreases the Pro-inflammatory Micro RNA-155 in the LPS-Treated Human Endothelial Cells.

Authors:  Mehdi Kalani; Hossein Hodjati; Mahdi Sajedi Khanian; Mehrnoosh Doroudchi
Journal:  Probiotics Antimicrob Proteins       Date:  2016-06       Impact factor: 4.609

2.  Lactobacillus acidophilus ATCC 4356 prevents atherosclerosis via inhibition of intestinal cholesterol absorption in apolipoprotein E-knockout mice.

Authors:  Ying Huang; Jinfeng Wang; Guihua Quan; Xiaojun Wang; Longfei Yang; Lili Zhong
Journal:  Appl Environ Microbiol       Date:  2014-09-26       Impact factor: 4.792

3.  The effects of probiotic bacteria on glycaemic control in overweight men and women: a randomised controlled trial.

Authors:  K L Ivey; J M Hodgson; D A Kerr; J R Lewis; P L Thompson; R L Prince
Journal:  Eur J Clin Nutr       Date:  2014-02-26       Impact factor: 4.016

Review 4.  Lactobacillus plantarum and Its Probiotic and Food Potentialities.

Authors:  Hamza Ait Seddik; Farida Bendali; Frédérique Gancel; Ismail Fliss; Giuseppe Spano; Djamel Drider
Journal:  Probiotics Antimicrob Proteins       Date:  2017-06       Impact factor: 4.609

5.  Lactobacillus plantarum 299v Supplementation Improves Vascular Endothelial Function and Reduces Inflammatory Biomarkers in Men With Stable Coronary Artery Disease.

Authors:  Mobin Malik; Tisha M Suboc; Sudhi Tyagi; Nita Salzman; Jingli Wang; Rong Ying; Michael J Tanner; Mamatha Kakarla; John E Baker; Michael E Widlansky
Journal:  Circ Res       Date:  2018-10-12       Impact factor: 17.367

6.  Probiotics, Irritable Bowel Syndrome, and Inflammatory Bowel Disease.

Authors:  Martin H. Floch
Journal:  Curr Treat Options Gastroenterol       Date:  2003-08

Review 7.  Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings.

Authors:  Lay-Gaik Ooi; Min-Tze Liong
Journal:  Int J Mol Sci       Date:  2010-06-17       Impact factor: 5.923

Review 8.  ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy.

Authors:  Colleen T Cole-Jeffrey; Meng Liu; Michael J Katovich; Mohan K Raizada; Vinayak Shenoy
Journal:  J Cardiovasc Pharmacol       Date:  2015-12       Impact factor: 3.105

Review 9.  The gut microbiome, kidney disease, and targeted interventions.

Authors:  Ali Ramezani; Dominic S Raj
Journal:  J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 10.121

10.  Lactobacillus casei modulates the inflammation-coagulation interaction in a pneumococcal pneumonia experimental model.

Authors:  Cecilia Haro; Julio Villena; Hortensia Zelaya; Susana Alvarez; Graciela Agüero
Journal:  J Inflamm (Lond)       Date:  2009-10-16       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.